1. Introduction

The use of effective cancer chemotherapy drugs is mainly hindered by their low aqueous solubility, which complicates their administration, and their high toxicity, necessary in regards to cancer cells but detrimental and the origin of severe side effects for healthy tissues. A wide range of pharmaceutical nanocarriers, such as polymeric or lipid nanoparticles or micelles [1–3] and even inorganic nanoparticles [4], have been screened for reducing the in vivo accumulation of therapeutic agents into the areas to be cured. Polymeric nanomaterials are very often composed of FDA-approved biodegradable polymers, such as poly(lactic acid) (PLA), poly(glicyclic acid) (PGA), and poly(e-caprolactone) (PCL). However, their structure and therefore their synthesis process have to be tailored for each specific application. Lipid materials are more versatile and present the advantage of a lower intrinsic toxicity, because of their compositions similar or close to those of physiological lipids.

Numerous lipid nanocarriers with different structures have been studied for therapy or imaging [5–7]: micelles [8], lipoproteins [9,10], liposomes [11], micro-emulsions [12] and nanoemulsions [13,14], solid-lipid nanoparticles (SLN) [6,15,16] and nanocapsules [17]. Because of the limited size of their core, micelles cannot store high drug payload. Lipoproteins must be isolated from fresh plasma or designed from synthetic peptides [18]. Due to their phospholipid bilayer and hydrophilic cavity, liposomes display outstanding properties for the encapsulation of hydrophilic/amphiphilic therapeutic agents. However, they are not optimized for the encapsulation of high concentrations of lipopholic drugs. They are not stable enough for being stored in injection-ready formulations for long durations, and their use usually requires the reconstitution of the solution just before injection to the patient. Lipid core nanocarriers present the advantage of a higher volume reservoir for lipophilic drug encapsulation. Nanocapsules have a liquid-lipid core encapsulated within a solid core.
polymeric or phospholipid shell [17]. Micro-emulsions (self-assembled, thermodynamically stable) [12] and nanoemulsions (thermodynamically unstable, requiring energy for their processing) [13,14] have a liquid core, whereas solid-lipid nanoparticles (SLN) have in principle a solid one [6,15,16]. However, the frontiers between the different categories of lipid particles are not so well defined. As an example, super-cooled liquid state has been observed in different SLN formulations. The solid crystalline core of SLN can present several drawbacks, such as problems of reproducibility in the particle growth, possibility of polymorphic transitions, which can induce drug expulsion during storage, and low drug incorporation capacities due to the crystalline structure [19]. Therefore, the concept of “nanostructured” lipid carriers has been introduced by Müller et al. [5]. The idea is to obtain lipid nanoparticles with a solid but not crystalline core, in order to improve the efficiency and stability of drug encapsulation.

In this manuscript, we report the design and in vivo bio-distribution of new lipid nanoparticles (LNP), which lipid core is composed of a mixture of oil and wax, solid at room temperature for improved stability and liquid at body temperature (~37–40 °C melting point). The core of the LNP therefore provides a reservoir suitable for the encapsulation and controlled release of lipophilic drugs and molecules. In order to demonstrate the potential of these new nanocarriers and to test the in vivo fate of the LNP, and the benefits of encapsulation on the drug properties (improved fluorescence quantum yield and reduced photobleaching) [20]. FLI now allows to scan in real time the bio-distribution of near infrared dye-labeled molecules (µM payloads) in whole body live mice in a few seconds with a few millimeters resolution [21–23]. FLI is a fast, low cost, sensitive, non-ionizing, non-invasive, and easy-handled screening technique.

Using DiD-loaded nanoparticles, the bio-distribution of LNP decorated by the cRGD peptide able to target αvβ3 integrins has therefore been studied in vivo in two mice models using the FLI technique. The functionalization of nanocarriers in order to improve their vectorization and targeting properties has been a major issue explored to improve therapy and diagnostics efficiencies in the last three decades [1–3]. αvβ3 Integrins are receptors over-expressed on the angiogenic vessels grown during tumor development [24,25]. Moreover, human membrane receptors are also expressed in 25% of human cancer cells of different types (malignoma, glioblastoma, ovarian, breast cancer) [24,25]. They therefore constitute targets of choice for favoring the specific binding and uptake in malignant cells of nanoparticles loaded with a drug or contrast agent. The well-known triad peptide sequence RGD (Arg-Gly-Asp), which recognizes the αvβ3 integrins has been identified 20 years ago [26], and its cyclic form c(RGDfK) designed from the peptides developed by Kessler’s group provides easy conjugation to imaging and/or therapeutic moieties [24,27,28]. Coating onto the LNP of the cRGD targeting ligand, the cRGD peptide negative control or a non-targeting –OH group is hereafter assessed by in vitro test on HEK293(β3) cells cultured, before the functionalized LNP are injected intravenously in two mouse models, HEK293(β3) and TS/A-pc. The HEK293(β3) cell line (human embryonic kidney) has been genetically modified to strongly express αvβ3 integrins and has been successfully used as a study model for a few years [29–31]. TS/A-pc (mice mammary carcinoma cells) is another model which express naturally αvβ3 integrins [32]. Whenever injected subcutaneously in a Nude mouse model, TS/A-pc cells will grow faster (10 days) than HEK293(β3) cells (6 weeks) before reaching the size at which tumor imaging is performed. It is important whenever designing a new fluorescent probe or a drug delivery vector to demonstrate its potentialities in different animal models. In this study, LNP-cRGD-specific targeting is studied in comparison with negative control LNP-cRAD and non-targeted LNP-OH in the two different mice models, HEK293(β3) and TS/A-pc, which can be targeted using the same ligand, but differ in their growing process.

2. Materials and methods

2.1. Materials

Suppocire NC™ is a kind gift from Gatéfossé (France), Myrj® 53 a kind gift from Croda Uniqema (France). The thio-acetylated peptides c(RGDfK(Ac-S-CH2CO)) (cRGD) and c(RADfK(Ac-S-CH2CO)) (cRAD) are purchased from Asynth service B.V. (The Netherlands). DiD is purchased from Invitrogen, soybean oil, ι-α-lecithin and other chemical products from Sigma–Aldrich (France). The DSPE-POE1000-maleimide surfactant is prepared starting from distearyl phosphatidyl ethanolamine (DSPE, Sigma–Aldrich) and NHS-POE1000-maleimide (NHS = N-succinimidyl ester, POE = poly(ethylene oxide), Nektar, USA). To 25 mg of distearyl phosphatidyl ethanolamine (DSPE) dissolved in 1 mL anhydrous dichloromethane are added 100 mg of NHS-POE1000-maleimide and 5 µl of triethylamine. The advancement of the reaction is controlled by thin layer chromatography. After 2 h stirring under argon, the solvent is evaporated under reduced pressure and the product dissolved in dichloromethane to yield a 2 mL solution that will be used directly in the functionalized formulations.

2.2. Preparation of DiD-loaded LNP

For preparation of a 2 mL dispersion batch of non-functionalized LNP, 150 mg of Suppocire® NC, 50 mg of soy bean oil, 138 mg of ι-α lecithin, and 800 nmol of DiD (766 µg) are dissolved in 1 mL of dichloromethane and mixed at 45 °C. After homogenization, the organic solvent is evaporated under reduced pressure and the lipid phase is crudely mixed with the continuous phase composed of 228 mg of Mirj® 53, 50 mg of glycerol and NaCl 154 mM (1.38 mL). For the functionalized formulations, the compositions of both the dispersed and continuous phases are slightly modified. In this case, for the preparation of a 2 mL dispersion batch of LNP-maleimide, 150 mg of Suppocire® NC, 50 mg of soy bean oil, 138 mg of ι-α lecithin, 49 mg of DSPE-POE1000-maleimide (880 µl of the solution prepared as described earlier), and 800 nmol of DiD (766 µg) are dissolved in 0.5 mL of dichloromethane and mixed at 45 °C. After homogenisation, the organic solvent is evaporated under reduced pressure, and the lipid phase is crudely mixed with the continuous phase composed of 207 mg of Mirj® 53, 50 mg of glycerol, and 1.36 ml of buffer (HEPES 0.05 M, EDTA 0.01 M, pH 7.4). After crude mixing at 45 °C of the dispersed and continuous phases, emulsification is carried out by sonication (AV505 Ultrasonic processor, Sonics, USA) performed at 40 °C for 5 min. A translucent blue solution is obtained, which is then purified by overnight extensive dialysis carried out at room temperature against 1000 times its volume in the appropriate aqueous buffer (NaCl for LNP, HEPES/EDTA buffer for LNP-maleimide) using a 12–14,000 Da MW cut-off membrane (ZelluTrans, Roth, France). When further functionalization is carried out, 600 µl of crude LNP-maleimide are diluted in 400 µl of grafting buffer (HEPES 0.05 M, EDTA 0.01 M, pH 7.4). In an aqueous -40 mM tris(2-carboxyethyl)phosphine solution, 3.75 µmol of the cRGD or cRAD peptides are dissolved and stirred for 30 min before being added to the LNP-maleimide solution. After stirring for 2 h in dark at ambient temperature, 7.5 µmol of 2-mercaptopo-ethanol are added to the dispersion in order to quench the surface maleimide groups that would have not reacted. After 30 min stirring in dark at room temperature, extensive dialysis against NaCl 154 mM is performed.
using a 12–14,000 Da MW cut-off membrane (ZelluTrans) to yield purified LNP-cRGD or LNP-cRAD. To obtain LNP-OH, only the quenching step with the addition of 2-mercaptoethanol and the further purification are performed. Finally, all the LNP dispersions are filtered through a 0.22-µm Millipore membrane for sterilization before characterization and/or injection.

2.3. Physico-chemical characteristics

Cryo-TEM (Transmission Electron Microscopy) analysis is performed using a MET microscope (JEOL 2100HC) with a LaB6 electron source operating at 200 kV. The sample is deposited onto a holey carbon grid, blotted to remove excess liquid, and frozen by plunging rapidly into liquid ethane (−185 °C). The hydrodynamic diameter and zeta potential of the lipid nanoparticles are measured with a Malvern Zeta Sizer Nano instrument (NanoZS, Malvern, UK) in 0.1 M PBS buffer. The absorbance and fluorescence measurements are performed, respectively, using a Cary 300 Scan (Varian, Massy, France) UV–visible spectrophotometer and a Perkin Elmer LS50B fluorimeter (Perkin, Courtaboeuf, France). The absolute fluorescence quantum yields QY are calculated by comparison with a standard of known QY (Nile blue perchlorate in ethanol (QY = 0.27) [33] at 600 nm excitation, as previously described [20].

2.4. Cell lines and culture conditions

HEK293[β3], stable transfectants of human β3 from the human embryonic kidney cell line (kindly provided by J.-F. Gourvest, Aventis, France), are cultured as previously described in DMEM supplemented with 1% glucose, 10% fetal bovine serum (FBS), penicillin (50 units/mL), and streptomycin (100 µg/mL) (1 mM CaCl2 and 1 mM MgCl2). They are then incubated for 15 min at 4 °C (binding analysis) or 1 h at 37 °C (internalization analysis) in the presence of either LNP-cRGD, LNP-cRAD, or LNP-OH at a concentration of 0.2 µM DiD and 141 µg/mL of total lipids. They are subsequently rinsed with PBS containing 1 mM CaCl2 and 1 mM MgCl2 and fixed (10 min with 0.5% paraformaldehyde). Nuclei are labeled with Hoechst 33342 (Sigma Aldrich, St. Quentin Fallavier, France) (5 µM) during 10 min. After being rinsed with PBS, coverslips are mounted in Mowiol. Fluorescence microscopy is performed on an Axioskop microscope (Zeiss, Jena, Germany) equipped with interference filters. Fluorescence images as well as black and white pictures are acquired by a back-thinned CCD camera (−80 °C ORCAII-BT-512G, Hamamatsu, Japan) fitted with high pass filter RG 9 (Schott, Jena, Germany) [29,30,32,34,35].

2.5. Fluorescence microscopy analysis of functionalized LNP incubated in the presence of HEK293[β3] cells

HEK293[β3] cells – 10⁶ per well – are grown on coverslips overnight at 37 °C, rinsed once with PBS, then with PBS containing 1 mM CaCl2 and 1 mM MgCl2. They are then incubated for 15 min at 4 °C (binding analysis) or 1 h at 37 °C (internalization analysis) in the presence of either LNP-cRGD, LNP-cRAD, or LNP-OH at a concentration of 0.2 µM DiD and 141 µg/mL of total lipids. They are subsequently rinsed with PBS containing 1 mM CaCl2 and 1 mM MgCl2 and fixed (10 min with 0.5% paraformaldehyde). Nuclei are labeled with Hoechst 33342 (Sigma Aldrich, St. Quentin Fallavier, France) (5 µM) during 10 min. After being rinsed with PBS, coverslips are mounted in Mowiol. Fluorescence microscopy is performed on an Axioskop microscope (Carl Zeiss, Jena, Germany). The same experiment is performed also in serum conditions (culture medium with 10% of fetal bovine serum).

2.6. Flow cytometry analysis of functionalized LNP incubated in the presence of HEK293[β3] cells

For binding analysis, adherent cells are resuspended with trypsin, washed once with cold PBS, and another time with PBS containing 1 mM CaCl2 and 1 mM MgCl2. One million cells in a final volume of 200 µL are resuspended in LNP suspension (0.2 µM DiD, 141 µg/mL total lipids) in PBS containing 1 mM CaCl2 and 1 mM MgCl2 and incubated 15 min at 4 °C. LNP solutions are removed and pellets care-fully rinsed twice with PBS containing 1 mM CaCl2 and 1 mM MgCl2 and fixed (10 min with 0.5% paraformaldehyde). Nuclei are labeled with Hoechst 33342 (Sigma Aldrich, St. Quentin Fallavier, France) (5 µM) during 10 min. After being rinsed with PBS, coverslips are mounted in Mowiol. Fluorescence microscopy is performed on an Axioskop microscope (Carl Zeiss, Jena, Germany). The same experiment is performed also in serum conditions (culture medium with 10% of fetal bovine serum).

2.7. In vivo fluorescence imaging

Female NMRI Nude mice (6–8 weeks old, JANVIER, Le Genest Saint Isle, France) receive a sub-cutaneous xenograft of HEK293[β3] cells (20 × 10⁶ per mouse) or TS/A-pc cells (10 × 10⁶ per mouse). After tumor growth, mice (n = 3 for each group) are anesthetized (isoflurane/oxygen 4%/3.5% for induction and 2% thereafter) and are injected intravenously in the tail vein with 200 µL of LNP suspension (10 nmol DiD, 7.1 mg of total lipids), then they are illuminated by 660-nm light-emitting diodes equipped with interference filters. Fluorescence images as well as black and white pictures are acquired by a back-thinned CCD camera (−80 °C ORCAII-BT-512G, Hamamatsu, Massy, France) fitted with high pass filter RG 9 (Schott, Jena, Germany) [29,30,32,34,35].

3. Results

3.1. Design and characterization of lipid nanoparticles

Numerous active pharmaceutical ingredients are efficient in vitro at the cellular level, but cannot be used in vivo because of their high hydrophobicity that precludes their direct administration. Nanoparticles with a lipid core constitute ideal cargo for the vectorization of high payloads of these lipophilic compounds. We here report the design of new lipid nanoparticles (LNP) based on the use of low cost, Generally Recognized As Safe (GRAS) ingredients, such as oil, lecithine, and poly(oxyethylene) (POE) surfactants. LNP are manufactured by sonication, a versatile and up-scalable process. The lipid core is composed of a mixture of oil and wax, solid at ambient temperature, but melting at body temperature (≈37–40 °C), which should favor both the stability of the colloidal suspension during storage and controlled drug delivery in vivo. LNP can moreover be efficiently loaded by a lipophilic dye, DiD, in order to allow their in vitro and in vivo tracking [20].

In practice, LNP are manufactured following the steps described in Scheme 1. The oily phase composed of lipids with very low aqueous solubility (soybean oil and Suppocire™ wax), phospholipids (lecithine), and the lipophilic molecule to be vectorized (in this...
work the DiD dye) is mixed with the continuous phase composed of physiological buffer, poly(oxyethylene) surfactant (Mirj\textsuperscript{53}, C\textsubscript{25}50 oxyethylene motifs), and glycerol. The role of glycerol is to facilitate the emulsification step, which is carried out at 45°C for 5 min ultrasonication (Scheme 1). A dispersion of lipid droplets encapsulating the DiD dye and stabilized in surface by the mixture of phospholipids (lecithine) and POE surfactants (Mirj\textsuperscript{53}) is thus obtained. The typical droplet size as measured by dynamic light scattering in NaCl 154 mM is 35 ± 2 nm, with a polydispersity index of 0.17 ± 0.02 (Table 1). The zeta potential of the particles is ~5 ± 2 mV, demonstrating that their surface can be considered as neutral.

In order to be able to graft targeting ligands, such as the cRGD peptide, 9.2% of Mirj\textsuperscript{53} is replaced by DSPE-POE\textsubscript{5000}-maleimide (DSPE = distearyl phosphatidyl ethanolamine), while keeping constant the total quantity of POE surfactants. DSPE-POE\textsubscript{5000}-maleimide is a surfactant which poly(oxyethylene) chain contains ~110 oxyethylene motifs (longer than the ~50 oxyethylene motifs of the Mirj\textsuperscript{53} surfactant) and to which is grafted a maleimide coupling group at the hydrophilic extremity. After dialysis purification of the LNP-maleimide particles, classical thiol-maleimide coupling is performed in the presence of 2-mercaptoethanol, cRGD-SH, or cRAD-SH, in order to lead, respectively, to non-targeting LNP-OH, targeting LNP-cRGD, or negative control LNP-cRAD (Scheme 1).

The functionalization of the LNP does not modify dramatically their physico-chemical properties, as reported in Table 1 and Fig. 1. The introduction of the DSPE-POE\textsubscript{5000}-maleimide surfactants in the particle shell that already contains Mirj\textsuperscript{53} does not increase the particle hydrodynamic diameter (35 ± 2 nm), probably because the long polymer chains are in a coiled configuration. The polydispersity index is slightly increased for LNP-maleimide and LNP-OH (Table 1), which could be indicative of a lower stability for these colloidal suspensions. Interestingly, the shape of the particles as observed by cryo-transmission electronic microscopy (cryo-TEM) is not spherical but rather the lipid droplets appear oblong (Fig. 1). Similar non-spherical shapes have been reported for SLN and other lipid nanoparticles when observed by this technique [15]. The introduction of the functional groups does not affect the zeta potential either, which remains close to neutrality (Table 1): the introduced peptides or hydroxyl functions are globally neutral at pH 7–8. Moreover, the encapsulation of the DiD dye is not affected by the surface functionalization, and the fluorophore displays similar optical properties once loaded within the LNP core.

### Table 1

| Particles      | Hydrodynamic diameter (nm)\textsuperscript{a} | Polydispersity index\textsuperscript{a} | Zeta potential (mV)\textsuperscript{a} | QY\textsuperscript{b} |
|---------------|---------------------------------|---------------------------------|---------------------------------|----------------
| LNP           | 35 ± 2                          | 0.17 ± 0.02                     | ~5 ± 2                          | 0.38          |
| LNP-maleimide | 34 ± 2                          | 0.21 ± 0.02                     | ~3 ± 2                          | 0.39          |
| LNP-OH        | 35 ± 2                          | 0.22 ± 0.02                     | ~3 ± 2                          | 0.39          |
| LNP-cRGD      | 35 ± 2                          | 0.16 ± 0.03                     | ~3 ± 2                          | 0.40          |
| LNP-cRAD      | 35 ± 2                          | 0.15 ± 0.03                     | ~3 ± 2                          | 0.40          |

\textsuperscript{a} The error bar represents the standard deviation for at least three measurements per batch on two different batches.

\textsuperscript{b} The fluorescence quantum yields (QY) of DiD-loaded LNP are recorded at 600 nm excitation; the estimated error on the values is 5%.
The maximum number of targeting peptides (cRGD or cRAD) grafted onto the nanoparticle surface can be estimated by the absorption and emission maximum, respectively, at 646 and 668 nm, similar fluorescence quantum yield, Table 1.

(absorption and emission maximum, respectively, at 646 and 668 nm, similar fluorescence quantum yield, Table 1).

The maximum number of targeting peptides (cRGD or cRAD) grafted onto the nanoparticle surface can be estimated by the absorption and emission maximum, respectively, at 646 and 668 nm, similar fluorescence quantum yield, Table 1.)
rough calculation of the number of maleimide groups incorporated in the LNP surface during the emulsification process. Assuming all the DSPE-POE5000-maleimide surfactants are incorporated in the LNP surface and for an estimated concentration of $1.2 \times 10^{16}$ particles/mL (35 nm diameter particles) [20], a maximum number of 208 maleimide groups and therefore cRGD or cRAD peptides per particle is obtained (roughly 1 function per 20 nm² on the particle surface, for a total of 3850 nm² per particle).

As already observed for DiD-loaded LNP [20], the LNP-cRGD, LNP-cRAD, and LNP-OH, functionalized particles display a high colloidal stability when dispersed in NaCl 154 mM: no modification of either the particle size or zeta potential have been observed for 1 month storage at 4°C in dark. Therefore, functionalized LNP can be confidently tested for in vivo and in vitro applications.

3.2. In vitro targeting and internalization of LNP

Functionalization of the LNP by the cRGD targeting ligand is first checked in vitro. Targeted LNP-cRGD, negative control LNP-cRAD, and non-functionalized LNP-OH are incubated in the presence of HEK293(β3) cells. The HEK293(β3) cell line has been genetically modified to over-express αvβ3 integrins. Fig. 2 summarizes the results obtained both by flow cytometry and fluorescence microscopy after incubation of $6.0 \times 10^{12}$ particles/mL (0.2 μM of DiD dye, 141 μg/mL of total lipids) with HEK293(β3) cells in the presence of 10% fetal bovine serum. The incubation at 4°C is suitable for studying specific targeting (Fig. 2A and B), whereas incubation at 37°C allows particle internalization (Fig. 2C and D). Both flow cytometry and fluorescence microscopy evidence specific HEK293(β3) targeting of cRGD-functionalized LNP, in comparison with LNP-cRAD and non-functionalized LNP-OH after 15 min of incubation at 4°C. The specific interaction of HEK293(β3) cells with LNP-cRGD leads to the internalization of the particles with an endosome-like pattern after 1-h incubation at 37°C, as evidenced by fluorescence microscopy (Fig. 2C). Pre-saturation of the HEK293(β3) cells with 10 μM free cRGD for 5 min before LNP-cRGD incubation inhibits cell fluorescence labeling (results not shown). The results are similar whatever absence or presence of 10% fetal bovine serum in cell culture medium, indicating that non-specific interactions should not occur between the LNP and serum proteins. The dense poly(oxyethylene) coating of the nanoparticles seems to be efficient in preventing protein binding.

3.3. In vivo targeting of LNP

The in vivo behavior of LNP is then assessed following their intravenous injection in the tail vein of Nude mice bearing HEK293(β3) xenografts in their right flank. The fluorescence images obtained at different times after LNP injection (50 μM DiD, 35 mg of total lipids) are presented in Fig. 3. Similarly to the

![Fig. 3. In vivo injection of LNP-cRGD (A), LNP-cRAD (B), or LNP-OH (C) (10 nmol DiD, 7.1 mg of lipids dispersed in 200 μL) in HEK293(β3) xenografted Nude mice. Fluorescence images (200 ms integration time, color scale with contrast fixed between 1836 and 59,641) are recorded at different times after injection and superimposed to visible light images (in white and black) (A–C). Tumor over skin fluorescence ratio (D) is calculated by drawing regions of interest (ROI). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](image)
results obtained on cell cultures in vitro, an active accumulation of cRGD-targeted particles is observed in the tumor area, in comparison with LNP-OH. The maximum of the fluorescence signal is achieved 24 h after injection, and the tumor is still clearly delimited 48 h after injection. Further quantification of the tumor over skin ratio 24 h after injection sustains LNP-cRGD targeting (T/S = 1.53 ± 0.07, n = 3) in comparison with non-functionalized LNP-OH (T/S = 1.18 ± 0.09, n = 3). Surprisingly, a slight effect of the cRAD peptide functionalization (T/S = 1.37 ± 0.09, n = 3) is observed in vivo (Fig. 3), which is far less pronounced in vitro on the percentage of LNP-cRAD binding and internalization (Fig. 2). However, the tumor over skin contrasts overall remain poor in the HEK293(β3) tumor model.

Another tumor model is therefore tested in vivo. The TS/A-pc model is issued from a mouse mammary cancer cell line, known to express low levels of αvβ3 integrins on the cell membrane. However, because of their murine origin, TS/A-pc tumors are growing much faster than the human HEK293(β3) xenografts (10 days for TS/A-pc, 6 weeks for HEK293(β3)). Fig. 4 presents the results obtained in vivo after injection of targeting LNP-cRGD, negative control LNP-cRAD, and non-functionalized LNP-OH (50 μM DiD, 35 mg of total lipids) in Nude mice bearing TS/A-pc tumors. As evidenced

![Fig. 4. In vivo injection of LNP-cRGD, LNP-cRAD, or LNP-OH (10 nmol DiD, 7.1 mg of lipids dispersed in 200 μL) in Nude mice carrying sub-cutaneous TS/A-pc tumors. (A) Fluorescence images obtained 24 h after injection evidence important accumulation of all the particles in the tumor area. Fluorescence images (20 ms integration time, color scale with contrast fixed between 2121 and 15,212) are superimposed to visible light images (in white and black). (B) Accumulation of all types of particles in tumor is confirmed by fluorescence images (20 ms integration time, color scale with contrast fixed between 2121 and 15,212, superimposed to visible light images) recorded after organ dissection (24 h after injection). The grid indicating the order of the organs is in (C). H: heart; Lu: lungs; Br: brain; Sk: skin; M: muscle; K: kidneys; AG: adrenal gland; Bl: bladder; I: intestine; Sp: spleen; P: pancreas; F: fat; St: stomach; U: uterus–ovaries; Li: liver; T: tumor. (D) Quantification of the fluorescence signal of the different organs after dissection (24 h after injection). Fluorescence is expressed in relative light unit per pixel (RLU/pix). Controls are non-injected mice. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](image-url)
by the fluorescence images 24 h after injection, contrarily to the HEK293(p3) tumors for which small active targeting of LNP-cRGD is achieved, accumulation of LNP in the TS/A-pc tumors is obtained whatever the particle coating (cRGD, cRAD, –OH) (Fig. 4A). This is also evidenced by the tumor over skin fluorescence ratio 24 h after injection: 2.60 ± 0.48 for LNP-cRGD (n = 3), 2.40 ± 0.13 for LNP-cRAD (n = 3), 2.61 ± 0.21 for LNP-OH (n = 3). Observation of the organs 24 h after injection and animal dissection confirms a similar tumor accumulation for the three coatings (Fig. 4B–D). The whole body and organ fluorescence images evidence a rather homogeneous bio-distribution of the fluorescence signal in areas different from the tumor and the brain. The brain is not labeled, indicating that the LNP cannot cross the Blood Brain Barrier. A few organs appear more fluorescently labeled: uterus/ovaries, adrenals, liver, and intestine. The intestine fluorescence signal cannot be attributed to auto-fluorescence from the food but is significantly related to a partial elimination of the LNP (Fig. 4D). The mouse plasma also displays important fluorescence levels 24 h after injection (Fig. 4D), which could be indicative of a long circulation time of the particles in blood.

4. Discussion

4.1. Specifications for efficient particle targeting

Nanocarriers dedicated to drug or contrast agent targeting and delivery in vivo (animal and ultimately human applications) should fulfill several specifications. First of all, these nanocarriers should of course display no toxicity at the administrated doses. It has to be kept in mind from the design of clinical grade particles that pharmaceutical approval will be necessary. Second, they should display prolonged circulation in blood in order to accumulate progressively in the diseased tissues, and ultimately reach specific delivery only in targeted cells [1,36].

Achieving prolonged circulation in blood implies several constraints on the physico-chemical parameters of the nanocarriers. First, the nanometer size (<100 nm) and second, colloidal stability (no risk of in vivo particle aggregation) are of tremendous importance for ensuring no risk of embolism and for potentially achieving targeted cell internalization. Moreover, the nanometer size has been demonstrated to favor passive accumulation of nanoparticles in tumors [37]. This process is accounted for by the increased porosity in the tumor vasculature, along with the low lymphatic drainage of cancer tissues, in comparison with the healthy ones (Enhanced Permeability and Retention (EPR) effect) [37]. Even if fenestrations of the vasculature at the tumor sites strongly depend on the cancer models [38], 20–100 nm range often appears as an optimal diameter for an efficient extravasation and retention of the nanoparticles from capillaries to the tumor interstitial tissues [39]. Particle charge constitutes the third key physico-chemical parameter to control the nanovector bio-distribution. Positively charged nanocarriers are known to be very efficiently stocked in the liver as soon as they are injected [40]. Coating of the particles by poly(oxyethylene) polymers has been a well-described strategy to limit opsonin binding and therefore rapid uptake of nanoparticles by the RES (Reticulo-Endothelial System) organs, such as liver, spleen, and bone marrow [1,2,41–43]. Mastering all these physico-chemical parameters (size, stability, surface charge, and coating) is therefore of tremendous importance for in vivo applications of nanovehicles.

4.2. Achieving in vivo specifications with LNP

The idea that long-lasting blood circulation will lead to a better tumor accumulation and targeting for oncology applications has driven the LNP design. The lipid nanoparticles described in this work are composed of vegetable oil and wax containing long chain triglycerides (LNP core), C16–C18 phosphatidylcholine (lecithine phospholipid), and poly(oxyethylene)-based surfactants. All these products are already approved by the FDA for human use. The similarity of structures of the LNP ingredients and naturally encountered lipids and phospholipids should ensure a good biocompatibility and metabolism of the LNP nanocarriers (further biocompatibility and cellular toxicity studies are in progress). Moreover, long chain triglycerides (LNP core), C16–C18 phosphatidylcholine (lecithine phospholipids, LNP shell), and poly(oxyethylene)-based surfactants (LNP shell) are ingredients known for promoting slow elimination from the blood circulation when used in emulsion formulations [16]. In addition to a suitable ingredient choice, new manufacturing process has to be used in order to achieve small particle size with high colloidal stability, and therefore long blood circulation time. Lipid nanovehicles have presently diameters classically around 70–200 nm, and few formulations below 50 nm have been described [6,15,19,44]. The use of very high surfactant concentrations should ensure a small particle size while maintaining their colloidal stability. Neutral surfactants are chosen in order to achieve a near-neutrality surface of the nanocarriers: (i) phospholipids (soybean lecithin) and (ii) poly(oxyethylene)-based surfactants known to improve the stealth character of nanocarriers because they reduce opsonin binding and particle macrophage uptake [1,2,41–43]. Several processes have been described for the preparation of nanometric emulsions and SLN: hot or cold homogenization, solvent emulsification/evaporation, and dilution of micro-emulsions. These methods classically rely on the solubilization of the surfactants in the aqueous phase or the use of organic solvents [6,15,19,44]. In this work, in order to be able to increase the phospholipid ratio in the LNP formulation (up to 6.9% w/w phospholipids for 10% w/w total lipids) and therefore achieve smaller nanoparticle size, lecithin is introduced in the oily phase, thanks to the solubilizing power of the mixture of soybean oil and wax. In order to obtain a dense poly(oxyethylene) coating on the particle surface, very high content of stearate-POE0000 (Myrj® 53, 11.4% w/w for 10% w/w total lipids) is used. Emulsification is achieved using the sonication technique. Different emulsification processes have been described for the production of nanoeomulsions. Low-energy processes, such as PIT (Phase Inverse Temperature) [17,44] or Catastrophic Phase Inversion (CPI) [45,46] are advantageous for the encapsulation of fragile drugs and macromolecules but are highly dependent on the formulation composition [44]. Moreover, the introduction of modified phospholipids for the surface functionalization of the nanocarriers by targeting ligands is rather difficult in these conditions. High energy methods encompass mainly high pressure homogenization and sonication [47]. One advantage of sonication, however not widely used, is the fact that low to large volumes of highly viscous solutions can be easily processed. Moreover, as a high energy method, it allows the manufacturing of a wide range of formulations, and the incorporation in the composition of maleimide modified surfactants for further grafting of targeting ligands on the nanoparticle does not modify the processing. Thanks to this new manufacturing process, particle size of 35 nm diameter can be easily achieved (Table 1, Fig. 1). Moreover, the colloidal stability of the formulation is more than 1 year for LNP [20] and at least 1 month for LNP-cRGD, LNP-cRAD, and LNP-OH kept at 4 °C. This very good colloidal stability should be accounted for, at least partly, by the very dense POE coating that prevents particle coalescence. The use of non-ionic POE and zwitterionic phospholipid (lecithine) surfactants ensures a particle charge as measured by zeta potential in solution close to neutrality (ζ = – 5 ± 2 mV). This should also limit opsonin binding whenever particles are in blood circulation. Therefore, LNP seem to fulfill the different chemico-physical constraints...
associated to in vivo applications of nanoparticles: small size, high colloidal stability, neutral charge, and POE coating. In addition, these sub-100-nm nanocarriers can be sterilized using microfiltration, a process easier to manipulate than thermal or X-ray treatments, which can destabilize the lipid nanoparticles [15,19].

4.3. In vivo bio-distribution of LNP

Indeed, the small size and the POE coating of LNP seem to limit protein adsorption onto the nanoparticle surface. No effect of serum addition is observed on the specific targeting and internalization of LNP-cRGD assessed in vitro while incubation in the presence of HEK293(b3) cells (Fig. 2). The functionalized LNP seem to have a relatively long blood half life since all the organs (except brain) are able to be fluorescently labeled at similar levels, and since the fluorescence signal is clearly evidenced in plasma 24 h after injection (Fig. 4). It should be underlined here that fluorescence imaging is still not an absolutely quantitative method to assess bio-distribution, mainly because the different tissues (blood, plasma, organs) absorb and diffuse visible light in different manners. However, it is possible to make relative comparisons for a same organ between different particles and a non-injected animal and to drive conclusions on the fluorescence evolution over time. Another point is that fluorescence imaging allows the in vivo tracking of the fluorescent dye, but not truly the nanovector it is loaded into, and which might dissociate in vivo. The encapsulation stability of the DiD dye in the LNP core has been demonstrated to be superior to 1 year at room temperature on the laboratory shelf [20]. A very stable fluorescence signal (less than 30% decay in 48 h at 37 °C) is observed when DiD-loaded LNP dispersions are incubated in human plasma or whole blood in vitro (data not shown). The fluorescence signal cannot come from free DiD dye in solution, since this dye is not fluorescent in aqueous medium [20]. Therefore, the stability of the fluorescence signal is indicative either of leakage of the dye from the LNP, but followed by its adsorption on plasma proteins, or indicative of the stability of the dye encapsulation within the particle core while in plasma. Combined with the fact that a high density POE coating is present on the surface of the particle, which should prevent protein binding (no effect of calf serum proteins has been observed in vitro binding study, see Section 3.2), and the fact that the lipid dye should have a very good affinity for the particle lipid core, we believe that the particle’s integrity is therefore probably maintained in vitro in plasma and blood for a few hours at least. In vivo, the particle fate can of course be very different. The hydrophilic counterpart of the DiD dye, Cy5, has been shown to be readily eliminated by the kidneys when injected free in vivo [no similar test can be carried out with the DiD dye because of its low water solubility] [35]. All these points could indicate that the DiD dye remains loaded within the LNP core for at least a few hours while in blood circulation and that LNP DiD-loading really allows the in vivo tracking of the functionalized nanovectors. Further pharmacokinetics experiments, particularly using radiolabeling to allow a “true” quantitative bio-distribution, are currently planned to check this hypothesis. Assuming that the fluorescence signal reflects the LNP bio-distribution, the nanovehicles seem to distribute quite uniformly in the body and have a long blood circulation time, whatever their functionalization (Figs. 3 and 4). Thorough data analysis shows that tumor is the most fluorescent tissue along with uterus/ovaries and adrenal glands. Uterus/ovaries [40] and adrenals [48] have already been noticed to accumulate efficiently nanoparticles. Other organs in which a significant fluorescent signal is observed are liver and intestine. It has to be noticed that in comparison with other previously described nanovehicles, number of which are known to accumulate in high doses in the liver [1,2,49], LNP accumulation in this RES organ is limited. There is no indication of a possible clearance of the fluorescence signal by the kidneys, which is consistent with the 35 nm diameter size of the LNP, larger than the few (1–3) nm of the DiD or Cy5 dyes. There rather exist signs indicative of a hepato-biliary metabolism mechanism, classical for lipids, such as the relatively important fluorescence signal in the intestine. This hypothesis is currently being checked by complementary experiments specially focused on that point. However, it already appears that ligand-functionalized LNP should present all the specifications for achieving in vivo specific targeting, all the more than the relatively small size of the particles (35 nm diameter), and therefore their high surface/volume ratio should allow the presentation at their surface of a relatively dense coating of targeting ligands (presumably 50–200 per particle).

4.4. cRGD targeting in HEK293(b3) and TS/A-pc models

In vitro test of cRGD-functionalized LNP in the presence of HEK293(b3) cells validates the functionalization step, as well as the specificity of αvβ3 integrin binding and internalization, in comparison with LNP-cRAD and LNP-OH. Once the functionalization of the particles assessed in vitro, in vivo tests are carried out using two different tumor models – HEK293(b3) and TS/A-pc – implanted subcutaneously in Nude mice. Both tumor models express αvβ3 integrins on the cell membranes [29–32]. In both cases, significant tumor over skin fluorescence signal is observed a few hours (6–48 h) following intravenous injection of LNP-cRGD (10 nmol of dye, 7.1 mg of total lipids). In the case of HEK293(b3), this fluorescence signal is more pronounced in the presence of LNP-cRGD, in the sense that the same injected doses of LNP-cRAD and LNP-OH lead to lower tumor over skin fluorescence ratio (LNP-cRGD: T/S = 1.53 ± 0.07 (n = 3), LNP-OH: T/S = 1.18 ± 0.09 (n = 3), LNP-cRAD: T/S = 1.37 ± 0.09 (n = 3) 24 h after injection). Concerning the TS/A-pc model, no specificity due to the particle functionalization is observed: tumor over skin fluorescence ratio is similar for LNP-cRGD (2.60 ± 0.48 (n = 3)), LNP-cRAD (2.40 ± 0.13 (n = 3)), LNP-OH (2.61 ± 0.21 (n = 3)). Both cell lines express αvβ3 integrins [29–32]; however, the growth of the tumor is very different in the two models. After sub-cutaneous injection in mice, the human HEK293(b3) cells that over-express high levels of integrin are growing slowly (≈6 weeks for reaching 5-mm-diameter tumor), inducing a well-organized and structured neo-angiogenic vessel network for tumor supply [29–31]. On the contrary, TS/A-pc cells grow very fast (≈10 days for reaching 5-mm-diameter tumor) and express low level of αvβ3 integrin: the fast-build angiogenic vessels display very leaky fenestrations [32]. In such a tumor model, nanoparticles are known to extravasate very efficiently due to the passive (i.e. non-targeted) EPR effect. This passive extravasation and tumor tissue accumulation of the particles could occur whatever the LNP coating groups and would account for the similar fluorescence over skin ratio obtained for LNP-cRGD, LNP-cRAD, and LNP-OH in the TS/A-pc model. In the HEK293(b3) model, particle passive accumulation due to the EPR effect should be reduced because of the tight endothelial junction of the well-built neo-angiogenic vessels. In addition, a strong captation of RGD-targeted nanoparticles can be obtained by the tumor cells themselves since they express high amounts of the αvβ3 integrin. Therefore, no significant EPR effect should occur, and it could become possible to assess a different particle behavior according to their coating. In this case, a slight augmented uptake is observed with LNP-cRGD in comparison with LNP-OH. Surprisingly, a small effect of the cRAD peptide functionalization is observed in vivo (Fig. 3), which is far less pronounced in vitro on the percentage of LNP-cRAD binding and internalization (Fig. 2). This could be explained by subtle modifications of the surface of the particles after addition of the different peptides, which may favor their bio-availability. These
first results underline the disparity that might exist between different study models, such as the slow-growing tumor model (HEK293(β3)) and the fast-growing tumor model (TS/A-pc). Future work should encompass the validation of functionalized LNP in an even more extended range of biological models, such as for example tumor-induced models.

These results constitute a first proof of concept of LNP vectorization for imaging and drug delivery purposes. Whatever the biological model used, improving targeting efficiency in the future will imply both an optimization of the number of targeted ligands present at the particle interface, and an optimization of their presentation pattern. It has been shown that the number of targeting ligands present on the surface of nanocarriers should be optimized to find out the right balance. In vitro targeting efficiency might increase with the density of ligands grafted onto the nanoparticle surface, but screening the POE coating to achieve high ligand density is detrimental for the plasma circulation of the vectors, leading ultimately to poor in vivo results [50]. In the present study, long POE5000 chains (DSPE-POE5000-maleimide, 9% of the whole POE coating of the particle) have been used to present the cRGD targeting ligands “above” the nanoparticle POE coating (MinJ35, POE2000), at a moderate ligand density of probably \( \approx 50–200 \) motifs per particle. It has been demonstrated that the length of the POE chain linking the ligand to the nanoparticles also displays an optimum: if the tethering spacer is too small, but also too long (because of folding), the ligand is embedded in the POE coating and cannot interact efficiently with the cell membrane [51]. Optimization of the ligand density and length of the POE tethering chain will be carried out in the future, but increasing the number of DSPE-POE-maleimide surfactants or modifying their nature could impact the particle stability, and this point has to be studied carefully. Concerning the presentation of the ligands, it has been shown by our group [29,52–54] and others [25,26,55] that multimeric presentation of the cRGD peptide favors the efficiency of the cRGD/\( \alpha_v \beta_3 \) integrin recognition and ultimately its internalization in the targeted cell. In particular, the use of a cyclodecapeptide scaffold allowing tetrameric presentation of cRGD [52–54] is expected in the future to improve the LNP targeting efficiency in comparison with the monomeric cRGD ligands used in this study. The results have also stressed out the need to compare active nanoparticle targeting obtained because of the presence of specific ligands, like cRGD, with nanovehicles functionalized by reliable negative control, like cRAD, since the simple addition of an organic coating on the surface may strongly affect the behavior of the particles. This observation should therefore be taken into consideration in further studies focused on the optimization of the number and presentation of the ligands onto the LNP surface.

Dye-loaded lipid nanoparticles can be used as in vivo imaging agents as themselves, but also constitute a proof-of-principle of the potentialities of cRGD-LNP nanocarriers for vectorizing other imaging agents or therapeutic drugs. Therapeutic applications will require suitable release of the transported active ingredient. Depending on the aimed therapeutic application, prolonged continuous plasma release or specific targeting followed by local release are desired. Study of LNP release profile is beyond the scope of the present work and will be addressed in the future. However, LNP vectorization seems promising for applications requiring an efficient and plasma-stable encapsulation of highly lipophilic loads, such as the DiD dye (log \( P \approx 10 \)). The preliminary bio-distribution results obtained in this study tend to demonstrate that the very strong lipophily of the DiD dye which is encapsulated within the oily core and not at the particle surface, and the high density of the LNP POE coating which prevents protein binding, should minimize any burst release effect observed for other particles such as liposomes [3], while lipophilic drug-loaded LNP circulate in plasma. However, once cells of interest are targeted (in this case \( \alpha_v \beta_3 \) integrin over-expressing cells), it might be highly desirable that particle release occurs. LNP release profile and mechanisms will be addressed in the future.

5. Conclusions

In conclusion, new lipid nanoparticles (LNP) responding to the specifications of in vivo applications have been designed: they are constituted of ingredients that have been approved by the FDA for human use, have a high colloidal stability, a small size (35 nm diameter), and a neutral POE coating (\( \zeta = -5 \) mV). They can be functionalized by different peptide ligands, such as cRGD known to specifically bind to \( \alpha_v \beta_3 \) integrins expressed in neo-angiogenic process and at the surface of numerous tumor cell lines [24,25], while keeping their functionality and targeting effect in vitro and in vivo. Further in vivo experiments are necessary to better assess LNP potentialities, especially as drug delivery systems. However, along with an easy to scale-up and very reproducible manufacturing process, based on low cost ingredients, LNP nanovehicles present the suitable physico-chemical parameters for realistic and promising in vivo applications.

Acknowledgements

This work is supported by the Commissariat à l’Énergie Atomique and the French National Research Agency (ANR) through CancerNet funding and Contract No. ANR-08-PNANO-006-02. We acknowledge Anne-Claude Couffin (CEA, LETI-DTBS) for helpful remarks and discussion in writing the manuscript.

References


